Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Botaretigene Sparoparvovec

Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx Ocular UK

Phase 3 Most advanced trial
MGTX Developer
2 Registered trials

What is Botaretigene Sparoparvovec?

Botaretigene sparoparvovec is an AAV5 viral vector gene therapy carrying the RPGR gene, delivered subretinally to the eye. It is being studied in X-linked retinitis pigmentosa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AAV5-hRKp.RPGR
Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Ophthalmology
Developer
MeiraGTx Ocular UK Ltd (MGTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
IIO8Q82SD1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04794101 Phase 3 X-Linked Retinitis Pigmentosa Active not recruiting MGTX
NCT06646289 Phase 2 X-Linked Retinitis Pigmentosa Active not recruiting MGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

X-Linked Retinitis Pigmentosa

More from MeiraGTx Ocular UK

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.

Follow MGTX, the company behind Botaretigene Sparoparvovec

See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.